SCHEMBL6095828

SCHEMBL6095828

CO/N=C(\C(=O)OC(=O)/C(=N\OC)c1csc(N)n1)c1csc(N)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
NR1I2 O75469 4/20 0.45
PGR P06401 1/20 0.45
PTGS2 P35354 1/20 0.45
LMNA P02545 3/20 0.45
GAA P10253 1/20 0.45
ITGB1 P05556 2/20 0.44
ITGA4 P13612 2/20 0.44
HTR2C P28335 1/20 0.42
ALB P02768 1/20 0.40
PPARG P37231 1/20 0.40
SLC22A6 Q4U2R8 1/20 0.40
SLC22A8 Q8TCC7 1/20 0.40
SLC22A11 Q9NSA0 1/20 0.40
PTGS1 P23219 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6791300 0.92 ITGB1 (0.46) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL7076742 0.91 MAPT (0.48) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL7076737 0.91 MAPT (0.48) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL8313617 0.88 MAPT (0.44) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL27360895 0.88 MAPT (0.44) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL10263157 0.86 MAPT (0.49) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL19236061 0.86 MAPT (0.48) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL968132 0.86 MAPT (0.59) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL9982497 0.86 MAPT (0.48) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL3929244 0.86 MAPT (0.48) MAPTALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129350-B2 Coupling process and intermediates useful for preparing cephalosporins PFIZER, INC. (US) 2006-10-31 US disclosed
US-20040167327-A1 Coupling process and intermediates useful for preparing cephalosporins ZOETIS SERVICES LLC 2004-08-26 US disclosed
EP-1339722-A1 COUPLING PROCESS AND INTERMEDIATES USEFUL FOR PREPARING CEPHALOSPHORINS Pfizer Products Inc. (US) 2003-09-03 EP disclosed
US-20020198375-A1 Coupling process and intermediates useful for preparing cephalosporins PFIZER INC. 2002-12-26 US disclosed
WO-2002046198-A1 COUPLING PROCESS AND INTERMEDIATES USEFUL FOR PREPARING CEPHALOSPHORINS PFIZER PRODUCTS INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167327-A1 Coupling process and intermediates useful for preparing cephalosporins CBR1, CBR3, CYP2B6 MAPT 4873/4885ALDH1A1 868/4885MEN1 2201/4885
US-20020198375-A1 Coupling process and intermediates useful for preparing cephalosporins CBR1, CBR3, CYP2B6 MAPT 4871/4885ALDH1A1 567/4885MEN1 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.